134 related articles for article (PubMed ID: 34044410)
1. Improving Survival in Lymphangioleio-myomatosis: A 16-Year Observational Study in a Large Cohort of Patients.
Harari S; Torre O; Elia D; Caminati A; Pelosi G; Specchia C; Zompatori M; Cassandro R
Respiration; 2021; 100(10):989-999. PubMed ID: 34044410
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis.
Harari S; Spagnolo P; Cocconcelli E; Luisi F; Cottin V
Curr Opin Pulm Med; 2018 Sep; 24(5):469-476. PubMed ID: 29927757
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
[TBL] [Abstract][Full Text] [Related]
4. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Neurohr C; Hoffmann AL; Huppmann P; Herrera VA; Ihle F; Leuschner S; von Wulffen W; Meis T; Baezner C; Leuchte H; Baumgartner R; Zimmermann G; Behr J
Respir Res; 2011 May; 12(1):66. PubMed ID: 21600034
[TBL] [Abstract][Full Text] [Related]
5. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
[TBL] [Abstract][Full Text] [Related]
6. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
7. COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.
Kato M; Kanehiro Y; Yoshimi K; Kodama Y; Sekiya M; Sato T; Takahashi K; Seyama K;
Respir Investig; 2018 Nov; 56(6):480-488. PubMed ID: 30143460
[TBL] [Abstract][Full Text] [Related]
8. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.
El-Chemaly S; Henske EP
Expert Rev Respir Med; 2015 Apr; 9(2):195-204. PubMed ID: 25757365
[TBL] [Abstract][Full Text] [Related]
9. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
[TBL] [Abstract][Full Text] [Related]
11. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.
Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Takada T; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Arai T; Sugimoto C; Hattori N; Watanabe K; Tamada T; Akazawa K; Tanaka T; Nakata K
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1182-1189. PubMed ID: 28752672
[TBL] [Abstract][Full Text] [Related]
14. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
15. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
[TBL] [Abstract][Full Text] [Related]
16. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.
Zhan Y; Shen L; Xu W; Wu X; Zhang W; Wang J; Li X; Yang Y; Tian X; Xu KF
Orphanet J Rare Dis; 2018 Feb; 13(1):34. PubMed ID: 29458386
[TBL] [Abstract][Full Text] [Related]
17. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
[TBL] [Abstract][Full Text] [Related]
18. Lymphangioleiomyomatosis treatment with sirolimus.
Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience.
Revilla-López E; Berastegui C; Méndez A; Sáez-Giménez B; Ruiz de Miguel V; López-Meseguer M; Monforte V; Bravo C; Pujana MA; Ramon MA; Gómez-Ollés S; Roman A;
Sci Rep; 2021 May; 11(1):10171. PubMed ID: 33986388
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
